Evidence map›Paper›PMID 34127865›Full record

ArticleNature protocols2021

Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy.

Samantha M Sarrett, Outi Keinänen, Eric J Dayts, Guillaume Dewaele-Le Roi, Cindy Rodriguez, Kathryn E Carnazza, Brian M Zeglis

Open access · greenAbstract read
In one paragraph

Article in Nature protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Development of anChemical & biomedical imaging · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. [RSC chemical biology · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Click chemistry and drug delivery: A bird's-eye view.Acta pharmaceutica Sinica. B · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Samantha M Sarrett *Department of Chemistry, Hunter College, City University of New York, New York, NY, USA.ORCID http://orcid.org/0000-0002-1326-8263
Outi Keinänen *Department of Chemistry, Hunter College, City University of New York, New York, NY, USA.ORCID http://orcid.org/0000-0002-3939-6706
Eric J DaytsDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.ORCID http://orcid.org/0000-0003-2226-1116
Guillaume Dewaele-Le RoiDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Cindy RodriguezDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Kathryn E CarnazzaBrain and Mind Research Institute & Appel Institute for Alzheimer's Disease Research, Weill Cornell Medical College, New York, NY, USA.
Brian M ZeglisDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA. bz102@hunter.cuny.edu.ORCID http://orcid.org/0000-0002-9091-744X
The Graduate Center, CUNY · USCity University of New York · USCornell University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Pretargeted Clinical Imaging of CA19.9 in Pancreatic CancerU01CA221046 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ZEGLIS, BRIAN MATTHEW · 2018 to 2022
$3.5M
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-TrastuzumabR01CA204167 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ULANER, GARY ALLAN · 2016 to 2020
$3.4M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
A PET Radiotracer for Diagnostic and Theranostics Imaging in Lyme DiseaseR21EB030275 · NIBIB · HUNTER COLLEGE · PI QIU, WEIGANG, ZEGLIS, BRIAN MATTHEW · 2020 to 2021
$429k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204167NCI NIH HHS R01 CA240963NCI NIH HHS R01 CA244327NCI NIH HHS U01 CA221046NIBIB NIH HHS R21 EB030275U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA20416U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA244327U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01CA221046U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB) R21EB030275
6 · The paper itself

Abstract

Radiolabeled antibodies have shown promise as tools for both the nuclear imaging and endoradiotherapy of cancer, but the protracted circulation time of radioimmunoconjugates can lead to high radiation doses to healthy tissues. To circumvent this issue, we have developed an approach to positron emission tomography (PET) imaging and radioimmunotherapy (RIT) predicated on radiolabeling the antibody after it has reached its target within the body. This in vivo pretargeting strategy is based on the rapid and bio-orthogonal inverse electron demand Diels-Alder reaction between tetrazine (Tz) and trans-cyclooctene (TCO). Pretargeted PET imaging and RIT using TCO-modified antibodies in conjunction with Tz-bearing radioligands produce high activity concentrations in target tissues as well as reduced radiation doses to healthy organs compared to directly labeled radioimmunoconjugates. Herein, we describe how to prepare a TCO-modified antibody (humanized A33-TCO) as well as how to synthesize two Tz-bearing radioligands: one labeled with the positron-emitting radiometal copper-64 ([

Indexed as

Cycloaddition ReactionElectronsPositron-Emission TomographyRadioimmunotherapyAnimalsClick ChemistryCyclooctanesMiceMice, NudeReproducibility of ResultsCyclooctanes

Identifiers

PMID34127865
PMCPMC8917728
OpenAlexW3169212438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.